BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 12-Dec-2019

(Continuation news of SQURPHARMA): the separated operations of various aspects of SFRL is a complex one. Since SPL holds 99.50% of the Paid up Capital of SFRL with only 0.50% being held by the minority shareholders, Board of Directors have recommended for amalgamation under provision of section 228 and 229 of the Companies Act 1994. Reason of merger between Square Herbal and Nutraceuticals Ltd. and Square Pharmaceuticals Ltd. is to reform Square Pharmaceuticals Ltd; (cont. 3)

SQURPHARMA 12-Dec-2019

(Continuation news of SQURPHARMA): whereby the Subsidiaries will merge with the Company, and the Company shall be the surviving entity. Our opinion is not modi?ed in respect of this matter. The financial statements reflects financial result of the amalgamated entity. Note 1.28 Merger with Square Formulations Ltd. and Square Herbal and Nutraceuticals Ltd.: As the project of Square Formulations Ltd. (SFRL) is located within the premises of Square Pharmaceuticals Ltd. (SPL) at Kaliakoir, (cont. 2)

SQURPHARMA 12-Dec-2019

Emphasis of Matter: We draw attention to Note 1.28 of the separate ?nancial statements which describe the amalgamation of the fully owned subsidiary the Square Formulations Ltd. and the Square Herbal and Nutraceuticals Ltd. with the Company. The Board of Directors of the Company in its meeting held on 16th October 2017 approved the amalgamation of the Company with the Subsidiaries (cont. 1)

SQURPHARMA 12-Dec-2019

(Continuation news of SQURPHARMA): into a diversi?ed high performance and value added company, Board of Directors considered a proposal for amalgation of Square Herbal and Nutraceuticals Ltd. with Square Pharmaceuticals Ltd. under provision of section 228 and 229 of the Companies Act 1994. The Process of Merger: After approval of Board of Directors and consent of minority shareholders, the Hon'ble High Court Division of the Supreme Court of Bangladesh has sanctioned (cont. 4)

SQURPHARMA 19-Nov-2019

Trading of the Shares of the Company will resume on 20.11.2019 after record date.

SQURPHARMA 18-Nov-2019

Trading of the shares of the Company will remain suspended on record date i.e., 19.11.2019.

SQURPHARMA 14-Nov-2019

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 17.11.2019 to 18.11.2019. Trading of the shares of the Company will remain suspended on record date i.e., 19.11.2019.

SQURPHARMA 14-Nov-2019

(Q1 Un-audited): Consolidated EPS was Tk. 4.25 for July-September 2019 as against Tk. 4.02 for July-September 2018; Consolidated NOCFPS was Tk. 4.14 for July-September 2019 as against Tk. 4.06 for July-September 2018. Consolidated NAV per share was Tk. 90.00 as on September 30, 2019 and Tk. 86.03 as on June 30, 2019.

SQURPHARMA 07-Nov-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2019 at 3.00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.

SQURPHARMA 23-Oct-2019

There will be no price limit on the trading of the shares of the Company today (23.10.2019) following its corporate declaration.

Previous Next page